Tetra Pharm Technologies Advances CB1 Antagonist, TPT0701, For Appetite Suppression Into Preclinical Testing

The Danish biopharmaceutical company, Tetra Pharm Technologies, proudly announces a significant milestone in the realm of appetite suppression research having developed a cutting-edge compound leveraging their innovative platform technology.

COPENHAGEN, Denmark, Feb. 8, 2024 /PRNewswire/ -- Following the successful filing of Intellectual Property (IP) for their applied platform technology targeting the endocannabinoid system (ECS), Tetra Pharm Technologies, is moving forward with its compound for appetite suppression, TPT0701.

Endocannabinoid system modulation has long been recognized as a promising avenue for appetite regulation. Through rigorous research and development efforts, Tetra Pharm Technologies has unlocked the potential of this biological system to address one of the most pressing health challenges of our time – excessive appetite and weight gain.

TPT0701 was originally designed in 2022 for obese patients suffering from schizophrenia but will now move into the development stage as appetite suppressing medication for general weight loss.

Dr. Morten Allesø, Chief Scientific Officer, Tetra Pharm Technologies, said: "With our new, proprietary platform technology as our secret weapon to unlock the endless possibilities of the endocannabinoid system, we are now ready to finalize TPT0701 for pre-clinical testing in 2024".

"Compounds, such as TPT0701, display physicochemical properties that render them difficult to formulate by means of conventional approaches. Our enabling platform technology, now with an IP application supporting it, can accommodate exactly these types of molecules and will help overcome otherwise hampering drug delivery challenges such as poor absorption and ultimately low bioavailability. Indeed, a drug is only as good as its delivery system, and with a check mark secured on both the formulation technology and the pharmacological mode of action established in early drug discovery, we are confident in the ongoing success of TPT0701 as it progresses through development," added Morten Allesø.

TPT0701 offers a novel approach to appetite suppression, aiming to provide individuals with a safe and effective means to manage their cravings and achieve their wellness goals. By specifically targeting the endocannabinoid system, Tetra Pharm Technologies' solution holds promise for combating obesity and related metabolic disorders, with far-reaching implications for public health.

"Obesity and its associated health risks have reached alarming levels worldwide, necessitating innovative approaches to address this pressing issue. Research and development are our top priority, and we will continue to invest in building our pipeline of new drug candidates targeting the endocannabinoid system and related disease indications", says Martin Rose, Chief Executive Officer, Tetra Pharm Technologies.

About Tetra Pharm Technologies ApS

Tetra Pharm Technologies is a Danish biopharmaceutical company established in 2018 with a vision to be a leader in research and development of pharmaceutical drugs for the treatment of diseases related to the endocannabinoid system. For more information, please visit www.tetrapharm.eu

For further information
Martin Caspersen
cap@tetrapharm.eu
+45 6122 4241

Photo - https://mma.prnewswire.com/media/2335238/Pipetting.jpg
Logo - https://mma.prnewswire.com/media/1988863/Tetra_Pharm_Technologies_Logo.jpg

SOURCE Tetra Pharm Technologies

First published on Thu, Feb 8, 2024

Enjoyed what you've read so far? Great news - there's more to explore!

Stay up to date with the latest news, a vast collection of tech articles including introductory guides, product reviews, trends and more, thought-provoking interviews, hottest AI blogs and entertaining tech memes.

Plus, get access to branded insights such as informative white papers, intriguing case studies, in-depth reports, enlightening videos and exciting events and webinars from industry-leading global brands.

Dive into TechDogs' treasure trove today and Know Your World of technology!

Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.

Tags:

Tetra Pharm Technologies Biopharmaceutical Endocannabinoid System (ECS) Intellectual Property (IP)

Join The Discussion

Dreame Launches Ultimate Roboticmower At CES 2026: All-Terrain, Wire-Free, With Built-In Security

Infosys And AWS Collaborate To Accelerate Enterprise Adoption Of Generative AI

Infosys And Cognition Announce Strategic Collaboration To Accelerate The AI Value Journey For Global Enterprises

Medicus Healthcare Solutions Releases A Comprehensive Report On The United States Physician Shortage

Motorola Brings New Accessories To The Moto Things Franchise At CES 2026